PURPOSE: To evaluate the accuracy of intraocular lens (IOL) power calculations between Hoffer Q and other formulas according to corneal curvature by comparing the results of cataract surgery and calculation of chosen formulas in short axial lengths. METHODS: We performed a retrospective analysis of patients who underwent cataract surgery from January 1st, 2012 to June 12th, 2012. The patients were selected if their axial length was below 23.00 mm and 77 patients (90 eyes) were included in the present study. The patients were divided into 2 groups according to mean corneal curvature below 44.0 D and over 45.0 D. IOL power was calculated using the Hoffer Q and SRK II, SRK-T and Holladay I formulas and the error between the calculations and refractive outcome of cataract surgery were measured. The accuracy of each formula was evaluated by comparing the error between the 2 groups. RESULTS: Hoffer Q formula showed a higher predictive accuracy than other formulas regardless of corneal curvature in eyes with short axial lengths (p < 0.001, p = 0.023). Particularly, SRK II, SRK-T and Holladay I showed a lower predictive accuracy in eyes with flat corneal curvature than Hoffer Q (p < 0.001, p = 0.215). CONCLUSIONS: In eyes with short axial lengths, preoperative predicted IOL power calculations showed better accuracy with Hoffer Q formula than SRK II, SRK-T and Holladay I formulas. SRK II, SRK-T and Holladay I formulas showed a lower predictive accuracy in flat corneal curvature eyes than steep corneal curvature eyes with short axial lengths. We hypothesize that SRK II, SRK-T and Holladay I tend to underestimate effective lens position in eyes with short axial lengths indicating Hoffer Q formula is more accurate.
Cataract ; Humans ; Lenses, Intraocular* ; Retrospective Studies

Background: and Purpose Serum insulin-like growth factor-1 (IGF-1) is known to have a neuroprotective effect. This study aimed to determine the effects of serum IGF-1 on the severity and clinical outcome of acute ischemic stroke (AIS). Methods: This study included 446 patients with AIS who were admitted to Hallym University Sacred Heart Hospital within 7 days of stroke onset from February 2014 to June 2017. Serum IGF-1 levels were measured within 24 hours of admission. Stroke severity was measured using the National Institutes of Health Stroke Scale (NIHSS) score at admission, and the functional outcome at 3 months after symptom onset was assessed using the modified Rankin Scale score. The effects of serum IGF-1 levels on stroke severity and 3-month functional outcomes were analyzed using multivariate logistic regression analysis. Results: This study evaluated 379 patients with AIS (age 67.2±12.6 years, mean±standard deviation; 59.9% males) after excluding 67 patients who had a history of previous stroke (n=25) or were lost to follow-up at 3 months (n=42). After adjusting for clinically relevant covariates, a higher serum IGF-1 level was associated with a lower NIHSS score at admission (adjusted odds ratio=0.44, 95% confidence interval=0.24–0.80, p=0.01), while there was no significant association at 3 months. Conclusions This study showed that a higher serum IGF-1 level is associated with a lower NIHSS score at admission but not at 3 months. Further studies are required to clarify the usefulness of the serum IGF-1 level as a prognostic marker for ischemic stroke.

Background: and Purpose Serum insulin-like growth factor-1 (IGF-1) is known to have a neuroprotective effect. This study aimed to determine the effects of serum IGF-1 on the severity and clinical outcome of acute ischemic stroke (AIS). Methods: This study included 446 patients with AIS who were admitted to Hallym University Sacred Heart Hospital within 7 days of stroke onset from February 2014 to June 2017. Serum IGF-1 levels were measured within 24 hours of admission. Stroke severity was measured using the National Institutes of Health Stroke Scale (NIHSS) score at admission, and the functional outcome at 3 months after symptom onset was assessed using the modified Rankin Scale score. The effects of serum IGF-1 levels on stroke severity and 3-month functional outcomes were analyzed using multivariate logistic regression analysis. Results: This study evaluated 379 patients with AIS (age 67.2±12.6 years, mean±standard deviation; 59.9% males) after excluding 67 patients who had a history of previous stroke (n=25) or were lost to follow-up at 3 months (n=42). After adjusting for clinically relevant covariates, a higher serum IGF-1 level was associated with a lower NIHSS score at admission (adjusted odds ratio=0.44, 95% confidence interval=0.24–0.80, p=0.01), while there was no significant association at 3 months. Conclusions This study showed that a higher serum IGF-1 level is associated with a lower NIHSS score at admission but not at 3 months. Further studies are required to clarify the usefulness of the serum IGF-1 level as a prognostic marker for ischemic stroke.